About Cardiome Pharma (NASDAQ:CRME)
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRME
CUSIPN/A
Phone604-677-6905
Debt
Debt-to-Equity Ratio2.47%
Current Ratio4.80%
Quick Ratio3.99%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$24 million
Price / Sales3.33
Cash FlowN/A
Price / CashN/A
Book Value$0.47 per share
Price / Book4.87
Profitability
EPS (Most Recent Fiscal Year)($0.90)
Net Income$-29,810,000.00
Net Margins-124.17%
Return on Equity-123.36%
Return on Assets-44.30%
Miscellaneous
Employees120
Outstanding Shares34,870,000
Cardiome Pharma (NASDAQ:CRME) Frequently Asked Questions
What is Cardiome Pharma's stock symbol?
Cardiome Pharma trades on the NASDAQ under the ticker symbol "CRME."
How were Cardiome Pharma's earnings last quarter?
Cardiome Pharma Co. (NASDAQ:CRME) released its quarterly earnings results on Tuesday, March, 13th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.05. The biopharmaceutical company had revenue of $7 million for the quarter, compared to analyst estimates of $7.94 million. Cardiome Pharma had a negative net margin of 124.17% and a negative return on equity of 123.36%. View Cardiome Pharma's Earnings History.
When is Cardiome Pharma's next earnings date?
What price target have analysts set for CRME?
3 brokerages have issued 1-year target prices for Cardiome Pharma's stock. Their predictions range from $5.00 to $10.00. On average, they expect Cardiome Pharma's stock price to reach $7.50 in the next year. View Analyst Ratings for Cardiome Pharma.
What are Wall Street analysts saying about Cardiome Pharma stock?
Here are some recent quotes from research analysts about Cardiome Pharma stock:
- 1. According to Zacks Investment Research, "Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), and a pre-clinical program directed at improving cardiovascular function. " (11/14/2017)
- 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: August 21, 2017, 09:42 ET Date and time of production: August 21, 2017, 09:42 ET Target Price / Valuation Methodology: Cardiome Pharma Corp. – CRME Discounted cash flow analysis supports an $8 valuation for CRME shares Our discounted cash flow (DCF) analysis leads us to a 12-month valuation of around $8/share for CRME, assuming continued progress on the Brinavess Canada and Xydalba launches along with a potential Trevyent launch in 2019. We estimate a weighted average cost of capital (WACC) of 11.2%, which assumes an 88% equity/total capital structure at a 10.3% cost of equity capital and a 12% debt/total capital structure at a 14% cost of debt. We use a long-term estimated tax rate of 22% and a terminal growth decline of 1% in our analysis. For cash management purposes, our analysis assumes an equity raise in 2H/17 but management has not publicly commented on the possibility of future capital raises. Risks to achieving Target Price / Valuation: Cardiome Pharma Corp. – CRME OUS payers and providers can be more difficult to predict – Given the relative lack of market data compared to the US coupled with a fragmented payer landscape, variability in physician training and standard of care modalities, and different preferences in patient populations in OUS markets, the marketability of a product in these environments can be more difficult to predict than in the US." (8/21/2017)
Who are some of Cardiome Pharma's key competitors?
Some companies that are related to Cardiome Pharma include BioXcel Therapeutics (BTAI), Zynerba Pharmaceuticals (ZYNE), Acer Therapeutics (ACER), Aldeyra Therapeutics (ALDX), Sierra Oncology (SRRA), Bellerophon Therapeutics (BLPH), Aeglea Bio Therapeutics (AGLE), Checkpoint Therapeutics (CKPT), BioDelivery Sciences International (BDSI), Adamis Pharmaceuticals (ADMP), Galectin Therapeutics (GALT), Affimed (AFMD), OncoMed Pharmaceuticals (OMED), ContraFect (CFRX), AcelRx Pharmaceuticals (ACRX), Axovant Sciences (AXON), Infinity Pharmaceuticals (INFI) and Trevena (TRVN).
Who are Cardiome Pharma's key executives?
Cardiome Pharma's management team includes the folowing people:
- W. James O'Shea, Independent Chairman of the Board
- William L. Hunter M.D., President, Chief Executive Officer, Director (Age 52)
- Justin A. Renz C.P.A., M.S.T., M.B., Chief Financial Officer (Age 45)
- Sheila M. Grant, Chief Operating Officer
- David D. McMasters J.D., Corporate General Counsel
- David C. Dean, Chief Business Development Officer
- Jennifer Archibald CPA, Chief Business Operations Officer
- Hugues Sachot, Chief Commercial Officer
- Richard M. Glickman LL.D., Lead Independent Director (Age 57)
- Mark H.N. Corrigan M.D., Independent Director (Age 60)
Has Cardiome Pharma been receiving favorable news coverage?
News headlines about CRME stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cardiome Pharma earned a media sentiment score of 0.15 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.40 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Cardiome Pharma's major shareholders?
Cardiome Pharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include
WESTFIELD CAPITAL MANAGEMENT COMPANY LP
(12.62%) and
WESTFIELD CAPITAL MANAGEMENT COMPANY LP
(12.62%). View Institutional Ownership Trends for Cardiome Pharma.
How do I buy shares of Cardiome Pharma?
Shares of CRME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cardiome Pharma's stock price today?
One share of CRME stock can currently be purchased for approximately $2.29.
How big of a company is Cardiome Pharma?
Cardiome Pharma has a market capitalization of $79.85 million and generates $24 million in revenue each year. The biopharmaceutical company earns $-29,810,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Cardiome Pharma employs 120 workers across the globe.
How can I contact Cardiome Pharma?
Cardiome Pharma's mailing address is 1441 Creekside Drive 6th Floor, Vancouver A1, V6J 4S7. The biopharmaceutical company can be reached via phone at 604-677-6905 or via email at [email protected]
MarketBeat Community Rating for Cardiome Pharma (CRME)
MarketBeat's community ratings are surveys of what our community members think about Cardiome Pharma and other stocks. Vote "Outperform" if you believe CRME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRME will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cardiome Pharma (NASDAQ:CRME) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Cardiome Pharma in the last 12 months. Their average twelve-month price target is $7.50, suggesting that the stock has a possible upside of 227.51%. The high price target for CRME is $10.00 and the low price target for CRME is $5.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.50 | $7.50 | $7.25 | $7.5833 |
| Price Target Upside: | 227.51% upside | 305.41% upside | 386.58% upside | 191.67% upside |
Cardiome Pharma (NASDAQ:CRME) Consensus Price Target History
Cardiome Pharma (NASDAQ:CRME) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Cardiome Pharma (NASDAQ:CRME) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Cardiome Pharma (NASDAQ CRME) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 50.49%
Cardiome Pharma (NASDAQ CRME) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Cardiome Pharma (NASDAQ CRME) News Headlines
| Source: |
|
Cardiome Pharma (NASDAQ:CRME) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cardiome Pharma (NASDAQ:CRME) Income Statement, Balance Sheet and Cash Flow Statement
Cardiome Pharma (NASDAQ CRME) Stock Chart for Sunday, April, 22, 2018
Loading chart…
